Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 20, 2025
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on November 11, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics and Transaction Data
The filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow).
| Metric | Value |
|---|---|
| Total Repurchase Programme Cap | DKK 20 billion |
| Sub-programme Cap (Nov 11, 2024 - Feb 3, 2025) | DKK 3,136,206,122.30 |
| Accumulated Repurchases (Since Feb 6, 2024) | DKK 19,336,248,035 |
| Total B Shares Repurchased (Since Feb 6, 2024) | 23,691,366 shares |
| Average Price (Since Feb 6, 2024) | DKK 816.17 per share |
| Treasury Shares Held | 24,835,924 B shares (0.6% of share capital) |
Recent Transaction Activity (Jan 13 - Jan 17, 2025)
- Jan 13: 98,000 shares @ DKK 618.00 (Value: DKK 60,563,841)
- Jan 14: 140,000 shares @ DKK 605.84 (Value: DKK 84,817,192)
- Jan 15: 70,000 shares @ DKK 597.96 (Value: DKK 41,856,988)
- Jan 16: 90,000 shares @ DKK 599.99 (Value: DKK 53,998,668)
- Jan 17: 100,000 shares @ DKK 589.09 (Value: DKK 58,908,517)
Material Changes and Programme Status
As of January 17, 2025, Novo Nordisk has repurchased approximately DKK 19.34 billion of the authorized DKK 20 billion, representing roughly 96.7% of the total programme value. The recent transactions indicate a downward trend in the average purchase price, with shares acquired in mid-January 2025 trading between DKK 589.09 and DKK 618.00, significantly lower than the programme's overall average of DKK 816.17.
Guidance, Outlook, and Risks
Outlook: The company expects to continue repurchasing B shares up to the remaining balance of the DKK 20 billion programme during the 12-month period ending February 5, 2025. The current sub-programme runs until February 3, 2025.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies. It notes that the repurchase programme is executed in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Programme Completion: Verify if the remaining ~DKK 664 million of the DKK 20 billion cap will be utilized before the February 5, 2025 deadline.
- Treasury Share Impact: Confirm the impact of the 0.6% treasury share holding on earnings per share (EPS) and total share count.
- Price Discrepancy: Investigate the significant difference between the recent transaction prices (~DKK 590-618) and the historical average price (DKK 816.17) to understand market volatility or timing of purchases.
- Future Capital Allocation: Determine management's strategy for capital allocation once the current DKK 20 billion buyback programme concludes.